

## Givlaari™ (givosiran)

When requesting Givlaari™ (givosiran), the individual requiring treatment must be diagnosed with an FDA-approved indication and meet the specific coverage guidelines and applicable safety criteria for the covered indication.

### FDA-Approved Indication

Givlaari is indicated for the treatment of adults with acute hepatic porphyria (AHP).

### Coverage Guidelines

#### Treatment of acute hepatic porphyria (AHP)

An individual must meet **BOTH** of the following criteria for approval:

- Is 18 years of age or older
- Givlaari is prescribed by or in consultation with one of the following specialist: gastroenterologist, hepatologist, a physician who specializes in acute hepatic porphyria

### Dosing Recommendation

The recommended dose of Givlaari is 2.5 mg/kg administered via subcutaneous injection once monthly.

### References

1. Givlaari™ injection solution [prescribing information]. Cambridge, MA: Alnylam Pharmaceuticals; November 2019.
2. Porphyria. U.S. National Library of Medicine; National Institutes of Health; Department of Health and Human Services. <https://ghr.nlm.nih.gov/condition/porphyria>. Last accessed: December 3, 2019.
3. Balwani M, Wang B, Anderson K, et al. Acute hepatic porphyrias: Recommendations for evaluation and long term management. *Hepatology*; 2017;66(4): 1314-1322.